ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...
My wife, who bore the brunt of my transformation into a grumpy badger, was the first to suggest I get a sleep study. She’d ...
According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...
Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...
For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for mo ...
Newsner Stories on MSN3d
Why do some people die in their sleep? Doctor explainsThe thought of dying in your sleep has probably crossed your mind more than once. It’s a terrifying idea — one you’d rather ...
Key Takeaways Untreated sleep apnea contributes to car crashesPatients who got no treatment were 21% more likely to be in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback